Skip to main content

Nifty sees worst Dec in 9 years | 264 stocks give double-digit weekly returns | Axis, Canara Bank top ideas for Jan 2023 |

To keep you updated, we send ET Markets Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here

DAILY BRIEF
Subscribe to ET Prime

Sat, Dec 31, 2022
#Q4Results#Coronavirus#StimulusPackage#ExpertViews#StockRecos
TOP OF THE DAY
264 stocks give double-digit weekly returns
Poonawalla Fincorp Ltd, Arvind Smartspaces, Suryoday Small Finance Bank, Sharda Cropchem, and Titagarh Wagons,...
Will Sensex be able to sustain its magic in 2023?
Rewind 2022: Lessons that stock market investors learnt
Promote significant reforms to elevate growth: Rajan
2 factors that may set trend in commodity market in 2023
Axis, Canara Bank top ideas for January 2023 series: Rupak De
Celebrating the success of Indian MSMEs
These QSR stocks can deliver over 48 % returns, say analysts
For Fastest News Updates, Incisive Stock Analysis by ET Experts and more.Download ETMarkets App!

Top Gainers

NSE
2 companies (largecap) appreciated more than 5%
New India Assurance 9.02%
GIC 6.43%
More from Gainers

Top Losers

NSE
1 company (largecap) price decreased more than -3%
Adani Transmission -3.01%
More from Losers

52 Week High

NSE
46 companies touched new 52-week high today
Avro India 19.98%
GRM Overseas 18.65%
More from 52 Week High
Financials, infra stocks to hog limelight next yr
One of the most prominent trends during 2022 was the jump in retail investors. This spike in number was also d...
Top 10 largecap stocks which may deliver up to 41%
Nomura lists 17 top stock picks for 2023. Here's the list
Seven stocks with upside potential of up to 60%

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
icon
Market Moguls
icon
Slideshow
icon
Video
Thank God, 2022 ride is over! Tighten belts for another roller coaster!
Top stock picks for 2023: RIL and Maruti among 9 stock ideas from ICICI Direct
Stock Radar: Here's why Bank of Baroda is a good short term buy
RECOMMENDATIONS
Techno Electric & Engineering Company Ltd.
Buy Techno Electric & Engineering Company, target price Rs 450: Edelweiss Securities
Buy
Birla Corporation Ltd.
Buy Birla Corporation, target price Rs 1185: Emkay Global Financial Services
Buy
ACC Ltd.
Buy ACC, target price Rs 2625: Emkay Global Financial Services
Buy
ABB India Ltd.
Buy ABB India, target price Rs 3200: Prabhudas Lilladher
Buy
Shree Cements Ltd.
Buy Shree Cements, target price Rs 23300: Emkay Global Financial Services
Buy
Nifty 50 sees worst December in 9 years!
The party spoiler for equities was yet again COVID. The staggering increase in the number of cases and deaths ...
Meditation helps this money manager to keep mentally fit
What investors can expect from the new year
Inflation, earnings among factors to drive US stocks in 2023
Quick Links
Markets Live | Market Stats | IPOs | Technicals | Commodities | Forex
Get In-depth analysis of stocks worth Rs 1499 complimentary with your ETPrime membership!
Know More
Follow Us:
Download ET Markets App:
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
More Newsletters: Daily Newsletter | Markets Morning | ET Investment Opportunities | Wealth | View all

© 2022 Times Internet Limited.

To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today. If you are having trouble viewing this newsletter, please click here, To unsubscribe or edit your subscriptions please click here

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More